Phaseline

Targets › PHEX

PHEX (Phosphate-regulating neutral endopeptidase PHEX): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Oct 2027.

Peptidase that cleaves SIBLING (small integrin-binding ligand, N-linked glycoprotein)-derived ASARM peptides, thus regulating their biological activity. Cleaves ASARM peptides between Ser and Glu or Asp residues. (UniProt, P78562)

Open in Phaseline: the race on PHEX, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, Los AngelesFerric Citrate
Iron-based phosphate binder and iron supplement
PHEXPhase 2Chronic Kidney DiseasesOct 2027

Conditions

Chronic Kidney Diseases (1)

Modalities

small molecule (1)

Companies

University of California, Los Angeles (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.